ADMA Biologics Lowers Full-Year Outlook Amid Competitive Uncertainty

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 4 days ago

0mins

ADMA-2.57%

Should l Buy ADMA?

Source: seekingalpha

Full-Year Outlook Downgrade: ADMA Biologics has lowered its FY26 revenue forecast to between $530 million and $560 million, below the consensus of $629.1 million, reflecting uncertainty in the competitive landscape that may hinder future revenue growth.
Mixed Quarterly Performance: The company reported Q1 earnings of $0.19 per share, in line with analyst expectations, but revenue of $114.5 million fell short of the anticipated $140 million, indicating weak market demand.
Divergent Product Performance: ASCENIV revenue grew 28% year-over-year to $97.5 million, while BIVIGAM revenue plummeted 54% to $15.4 million, highlighting disparities in market performance across product lines that could impact overall profitability.
Increased R&D Spending: The company projects adjusted net income for 2026 to be between $170 million and $200 million, down from $255 million, primarily due to increased R&D expenditures related to the SG-001 program, reflecting ongoing investment in new product development.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ADMA

About ADMA

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Three Stocks Added to Zacks Rank #5 (Strong Sell) List

7 hours agoNASDAQ.COM

ADMA Biologics: ADMA Biologics, Inc. has seen its current year earnings estimate revised downward by 12.5% over the last 60 days, indicating a decline in market confidence regarding its future profitability, which may pressure its stock price.
Aptiv Components: Aptiv PLC's current year earnings estimate has been cut by 24.1% in the past 60 days, highlighting increasing challenges in the automotive sector that could impact its market performance and investor confidence.
Astec Industries: Astec Industries, Inc. has experienced a nearly 4% downward revision in its current year earnings estimate over the last 60 days, reflecting weakness in the construction equipment market that may negatively affect its sales and profitability.
Impact of AI Revolution: While the AI revolution has already created many millionaires, the well-known stocks may not continue to deliver the biggest profits, prompting investors to focus on emerging companies to seize future growth opportunities.

Rosen Law Firm Investigates ADMA Biologics for Misleading Information

22 hours agoGlobenewswire

Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potentially issuing materially misleading business information, which poses a risk of securities claims for shareholders.
Stock Price Impact: On March 24, 2026, ADMA Biologics' stock fell by 16.6% after short seller Culper Research alleged the company engaged in channel stuffing to inflate revenue growth, resulting in direct financial losses for investors.
Class Action Preparation: The Rosen Law Firm is preparing a class action to seek recovery of investor losses, allowing affected shareholders to participate without any upfront costs, thus providing legal support opportunities.
Firm's Track Record: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its strong capabilities and successful track record in the securities litigation field.

ADMA Biologics Under Investigation for Securities Violations

3 days agoGlobenewswire

Investigation Launched: Lowey Dannenberg P.C. is investigating ADMA Biologics for potential violations of federal securities laws, raising serious concerns about the company's financial transparency and potentially undermining investor confidence.
Channel Stuffing Allegations: A report by Culper Research claims that in 2025, ADMA Biologics induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, allegedly inflating revenue and resulting in a real growth of -3% instead of the reported 20%.
Financial Impact: Had ADMA Biologics not engaged in this alleged channel stuffing scheme, it would have faced a 3% revenue decline in 2025, indicating significant discrepancies in financial reporting that could lead to investor losses exceeding $50,000.
Legal Consequences: This investigation could result in legal action against ADMA Biologics, further damaging its reputation and affecting stock prices, prompting investors to closely monitor developments to assess potential risks.

Investigation into ADMA Biologics for Securities Violations

3 days agoGlobenewswire

Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, focusing on allegations that the reported 20% revenue growth in 2025 was a result of a channel stuffing scheme to mask declining demand.
Revenue Growth Concerns: According to a report by Culper Research, ADMA allegedly induced a distributor to stockpile ASCENIV by offering rebates and extended payment terms, which allowed the company to inflate revenue figures; without this scheme, it would have faced a 3% revenue decline in 2025.
Stock Price Plummet: This news caused ADMA's stock price to drop by 29% over two trading days, falling from $13.59 per share on March 23, 2026, to $9.63 per share on March 25, indicating significant market concerns regarding the company's financial health.
Legal Options for Investors: Investors are encouraged to submit their information for legal assistance, with BFA offering representation on a contingency fee basis, highlighting their commitment to protecting shareholder rights and interests.

Rosen Law Firm Investigates ADMA Biologics for Potential Securities Claims

3 days agoPRnewswire

Securities Claims Investigation: Rosen Law Firm has announced an investigation into ADMA Biologics for potentially issuing materially misleading business information, which could severely impact the company's reputation and stock price if proven true.
Stock Price Plunge: On March 24, 2026, ADMA Biologics' shares fell by 16.6% after short seller Culper Research alleged that the company engaged in channel stuffing to inflate revenue, directly affecting investor confidence and market performance.
Class Action Preparation: The Rosen Law Firm is preparing a class action to seek compensation for affected investors, with no out-of-pocket fees required, which is likely to attract more shareholders impacted by the allegations.
Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.